Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib
Clinical trial NCT04769388 · COMPLETED
Trial details
- NCT number
- NCT04769388
- Sponsor
- Beijing Cancer Prevention & Treatment Society
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-28
- Primary completion
- 2026-01-24
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.